|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Diltiazem#Contraindications]] |
| {{Diltiazem}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==CONTRAINDICATIONS==
| |
| | |
| Diltiazem hydrochloride injection is contraindicated in:
| |
| | |
| 1-Patients with [[sick sinus syndrome]] except in the presence of a functioning ventricular pacemaker.
| |
| 2-Patients with [[second-degree AV block|second-]]or [[third-degree AV block]] except in the presence of functioning ventricular pacemaker.
| |
| 3-Patients with severe [[hypotension ]]or [[cardiogenic shock]].
| |
| 4-Patients who have demonstrated [[hypersensitivity ]]to the drug.
| |
| 5-Intravenous diltiazem and intravenous beta-blockers should not be administered together or in close proximity (within a few hours).
| |
| 6-Patients with[[ atrial fibrillation]] or [[atrial flutter]] associated with an accessory bypass tract such as in [[WPW ]]syndrome or short PR syndrome.
| |
| As with other agents which slow AV nodal conduction and do not prolong the refractoriness of the accessory pathway (eg, [[verapamil]], [[digoxin]]), in rare instances patients in [[atrial fibrillation]] or [[atrial flutter]] associated with an accessory bypass tract may experience a potentially life-threatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection. As such, the initial use of diltiazem hydrochloride injection should be, if possible, in a setting where monitoring and resuscitation capabilities, including DC [[cardioversion]]/[[defibrillation]], are present (see OVERDOSAGE). Once familiarity of the patient's response is established, use in an office setting may be acceptable.
| |
| 7-Patients with [[ventricular tachycardia]]. Administration of other [[calcium channel blockers]] to patients with [[wide complex tachycardia]] (QRS = 0.12 seconds) has resulted in hemodynamic deterioration and ventricular fibrillation. It is important that an accurate pretreatment diagnosis distinguish wide complex QRS tachycardia of supraventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DILTIAZEM HYDROCHLORIDE INJECTION [AKORN, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81c5cf23-a6f8-454a-9575-d01edf49ed34 | publisher = | date = | accessdate = 5 March 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |